Inhibrx Biosciences, Inc. (INBX) Stock Analysis and Metrics

Inhibrx Biosciences

NASDAQ: INBX

$81.57 ▼ -3.43 (-4.04%)

At close: Jul 24, 2026 · 3:59 PM UTC

Financial Ratios

Market Cap1.27 Bn

P/E-9.08

P/S908.53

Div. Yield0.00

Total Debt (Qtr)100.56 Mn

Add ratio to table…

About

Inhibrx Biosciences, Inc. is a clinical stage biopharmaceutical company focused on discovering and developing novel biologic therapeutics. The company uses its proprietary modular protein engineering platforms to design product candidates that target validated disease mechanisms with high unmet need. Its pipeline consists of two clinical stage programs: ozekibart, a tetravalent agonist of death receptor 5, and INBRX 106, a hexavalent agonist of OX40. Both candidates are being evaluated in various solid tumor indications including chondrosarcoma, Ewing sarcoma, colorectal cancer and non small cell lung cancer. The company is headquartered in La Jolla, California and operates as a standalone publicly traded entity after the spin off from its former parent in May 2024. Inhibrx states that its mission is to bring effective biologic treatments to patients with life threatening conditions by advancing its lead programs and applying its technology to create next generation therapeutics.

Inhibrx Biosciences, Inc. does not yet have any approved products on the market and therefore does not generate product sales revenue. The company finances its research and development activities primarily through proceeds from public equity offerings and the potential receipt of milestone or royalty payments from future collaboration agreements. The management team indicates that it will pursue strategic partnerships when it believes such arrangements can accelerate development timelines or enhance the commercial value of approved candidates. In addition, the company notes that it continuously seeks to improve operational efficiency to maximize the value of the capital it raises.

Inhibrx Biosciences, Inc. occupies a niche in the biotechnology sector where it leverages its proprietary modular protein engineering platforms to create multi specific biologics with tailored valency. This approach aims to improve therapeutic index over conventional bivalent antibodies. The company faces competition from a range of large and small firms that are also pursuing sdAb based platforms, antibody discovery and immunotherapy approaches. Notable competitors include Crescendo Biologics, Molecular Partners, Regeneron Pharmaceuticals, Adimab LLC, Genmab, Macrogenics, Merus, Numab Therapeutics, Amgen, Xencor and Zymeworks. In the autoimmune disease area, competitors include Sanofi, Amgen, AstraZeneca, Roche, Pfizer, Merck, Novartis, Candid Therapeutics, Hinge Bio and Apogee Therapeutics. Inhibrx believes its competitive advantages lie in its innovative platform technology, the expertise of its leadership team drawn from major pharmaceutical firms and its growing patent estate that protects its core technologies and product candidates.

Inhibrx Biosciences, Inc. currently does not have commercial products and therefore does not serve a traditional customer base. Its activities are focused on conducting clinical trials that involve patients suffering from refractory solid tumors such as chondrosarcoma, Ewing sarcoma, colorectal cancer and non small cell lung cancer. The company works with clinical trial sites, investigators and contract research organizations to administer its investigational therapies and collect safety and efficacy data. It also interacts with regulatory agencies such as the FDA to obtain guidance on trial design and potential pathways for approval. No specific customer names are disclosed in the filing.

Investment Thesis

▲ Bull case

Inhibrx Biosciences has generated compelling interim clinical data for its lead candidate INBRX-106 in the HexAgon study, demonstrating a 22.6% absolute improvement in confirmed objective response rate (44.0% vs 21.4%) in first-line PD-L1 positive HNSCC when combined with pembrolizumab versus pembrolizumab monotherapy alone, with three complete responses observed in the combination arm versus none in the control arm, suggesting a potential paradigm shift in immunotherapy efficacy for checkpoint-sensitive cancers that the market has not fully priced into the valuation despite the drug's novel hexavalent OX40 agonist mechanism designed to overcome limitations of traditional bivalent approaches.
The company's strategic plan to initiate Phase 3 of the HexAgon study in Q3 FY26 and expand INBRX-106 into front-line metastatic NSCLC by 2027, combined with exploratory combinations with vaccines, T-cell engagers, and CAR-T therapies, positions INBRX-106 as a potential backbone immunotherapy enhancer rather than a single-indication asset, with the hexavalent sdAb platform enabling tunable valency for optimal T-cell costimulation across multiple immune oncology contexts, a catalyst underappreciated by investors focused solely on near-term HNSCC data.
Inhibrx's financial position shows significant strengthening, with cash and cash equivalents increasing to $161.7 million as of March 31, 2026 from $124.2 million at December 31, 2025, bolstered by the $75.0 million gross proceeds from the First Amendment to the Loan and Security Agreement with Oxford Finance on March 18, 2026, providing ample runway to fund multiple Phase 2/3 trials in HNSCC, NSCLC, and combination studies without immediate dilution risk, despite the R&D expense reduction reflecting disciplined capital allocation after the INBRX-101 sale to Sanofi.
The emerging interest from major pharmaceutical companies including Merck KGaA, Ono Pharmaceutical, and potential suitors like Eli Lilly, AstraZeneca, Pfizer, and J&J for INBRX-106, coupled with Stifel's price target increase to $300 and projection of ozekibart exceeding $10 billion in annual sales, indicates credible acquisition or partnership potential that remains undervalued in the current market cap, especially given INBRX-106's mechanism to enhance Keytruda's efficacy in a $32 billion immunotherapy franchise facing patent expiration in 2028.
Ozekibart (INBRX-109) demonstrates broader pipeline value beyond its chondrosarcoma focus, with promising CRC data showing approximately 70% of evaluable patients receiving it as fourth-line therapy and 80% having prior irinotecan progression, alongside plans to discuss accelerated FDA pathways for refractory Ewing sarcoma and fourth-line CRC in H2 FY26, plus a submitted BLA for conventional chondrosarcoma in April 2026, creating multiple near-term inflection points that derisk the pipeline and support the company's claim of OX40 agonism having greatest curative potential in earlier-stage disease settings.

Inhibrx Biosciences has generated compelling interim clinical data for its lead candidate INBRX-106 in the HexAgon study, demonstrating a 22.6% absolute improvement in confirmed objective response rate (44.0% vs 21.4%) in first-line PD-L1 positive HNSCC when combined with pembrolizumab versus pembrolizumab monotherapy alone, with three complete responses observed in the combination arm versus none in the control arm, suggesting a potential paradigm shift in immunotherapy efficacy for checkpoint-sensitive cancers that the market has not fully priced into the valuation despite the drug's novel hexavalent OX40 agonist mechanism designed to overcome limitations of traditional bivalent approaches.
The company's strategic plan to initiate Phase 3 of the HexAgon study in Q3 FY26 and expand INBRX-106 into front-line metastatic NSCLC by 2027, combined with exploratory combinations with vaccines, T-cell engagers, and CAR-T therapies, positions INBRX-106 as a potential backbone immunotherapy enhancer rather than a single-indication asset, with the hexavalent sdAb platform enabling tunable valency for optimal T-cell costimulation across multiple immune oncology contexts, a catalyst underappreciated by investors focused solely on near-term HNSCC data.
Inhibrx's financial position shows significant strengthening, with cash and cash equivalents increasing to $161.7 million as of March 31, 2026 from $124.2 million at December 31, 2025, bolstered by the $75.0 million gross proceeds from the First Amendment to the Loan and Security Agreement with Oxford Finance on March 18, 2026, providing ample runway to fund multiple Phase 2/3 trials in HNSCC, NSCLC, and combination studies without immediate dilution risk, despite the R&D expense reduction reflecting disciplined capital allocation after the INBRX-101 sale to Sanofi.
The emerging interest from major pharmaceutical companies including Merck KGaA, Ono Pharmaceutical, and potential suitors like Eli Lilly, AstraZeneca, Pfizer, and J&J for INBRX-106, coupled with Stifel's price target increase to $300 and projection of ozekibart exceeding $10 billion in annual sales, indicates credible acquisition or partnership potential that remains undervalued in the current market cap, especially given INBRX-106's mechanism to enhance Keytruda's efficacy in a $32 billion immunotherapy franchise facing patent expiration in 2028.
Ozekibart (INBRX-109) demonstrates broader pipeline value beyond its chondrosarcoma focus, with promising CRC data showing approximately 70% of evaluable patients receiving it as fourth-line therapy and 80% having prior irinotecan progression, alongside plans to discuss accelerated FDA pathways for refractory Ewing sarcoma and fourth-line CRC in H2 FY26, plus a submitted BLA for conventional chondrosarcoma in April 2026, creating multiple near-term inflection points that derisk the pipeline and support the company's claim of OX40 agonism having greatest curative potential in earlier-stage disease settings.

▼ Bear case

Inhibrx Biosciences' HexAgon study Phase 2 data remains immature and limited, with only 53 of 68 enrolled patients (78%) having reached the maturity threshold for confirmed response analysis as of May 7, 2026, leaving 15 patients unevaluable due to insufficient follow-up, and the reported 44.0% vs 21.4% response rate based on this subset risks overestimation if the remaining patients exhibit divergent outcomes, a concern amplified by the absence of PFS or OS data which are critical for oncology valuation and not expected until Q4 FY26.
The company's reliance on combination with pembrolizumab for INBRX-106's efficacy creates significant commercial and regulatory dependency on Merck's Keytruda, which faces biosimilar competition starting in 2028 that could erode the $30+billion annual sales foundation underpinning the combination's value proposition, yet Inhibrx has not disclosed any monotherapy data or standalone efficacy signals for INBRX-106 to de-risk this partnership vulnerability.
Inhibrx's balance sheet reveals a deteriorating financial position despite increased cash, with long-term debt rising to $175.0 million as of March 31, 2026 from $100.6 million at December 31, 2025 due to the Oxford Finance agreement, and stockholders' equity shifting to a $21.0 million deficit from $8.0 million surplus, indicating growing financial leverage that could constrain future R&D investment if clinical milestones are delayed or financing terms become unfavorable.
The ozekibart CRC data, while showing encouraging activity in heavily pretreated patients, lacks comparative arm data or statistical significance testing in the April 2026 update, with the 70% fourth-line usage and 80% prior irinotecan progression reflecting a highly selected population where responses may not generalize to earlier lines of therapy, and the company's plans to pursue first-line registrational trials in CRC face steep competition from established regimens and emerging doublet/triplet combinations that may limit ozekibart's incremental benefit.
Inhibrx's pipeline breadth remains narrow with only two clinical-stage candidates (ozekibart and INBRX-106), both dependent on multivalent sdAb platform success, and the absence of recent updates on preclinical programs or platform expansion efforts raises concerns about long-term sustainability beyond these two assets, especially given the company's history of divesting INBRX-101 to Sanofi and the potential for platform limitations to hinder next-generation candidate generation if the current candidates fail to deliver transformative results.

Inhibrx Biosciences' HexAgon study Phase 2 data remains immature and limited, with only 53 of 68 enrolled patients (78%) having reached the maturity threshold for confirmed response analysis as of May 7, 2026, leaving 15 patients unevaluable due to insufficient follow-up, and the reported 44.0% vs 21.4% response rate based on this subset risks overestimation if the remaining patients exhibit divergent outcomes, a concern amplified by the absence of PFS or OS data which are critical for oncology valuation and not expected until Q4 FY26.
The company's reliance on combination with pembrolizumab for INBRX-106's efficacy creates significant commercial and regulatory dependency on Merck's Keytruda, which faces biosimilar competition starting in 2028 that could erode the $30+billion annual sales foundation underpinning the combination's value proposition, yet Inhibrx has not disclosed any monotherapy data or standalone efficacy signals for INBRX-106 to de-risk this partnership vulnerability.
Inhibrx's balance sheet reveals a deteriorating financial position despite increased cash, with long-term debt rising to $175.0 million as of March 31, 2026 from $100.6 million at December 31, 2025 due to the Oxford Finance agreement, and stockholders' equity shifting to a $21.0 million deficit from $8.0 million surplus, indicating growing financial leverage that could constrain future R&D investment if clinical milestones are delayed or financing terms become unfavorable.
The ozekibart CRC data, while showing encouraging activity in heavily pretreated patients, lacks comparative arm data or statistical significance testing in the April 2026 update, with the 70% fourth-line usage and 80% prior irinotecan progression reflecting a highly selected population where responses may not generalize to earlier lines of therapy, and the company's plans to pursue first-line registrational trials in CRC face steep competition from established regimens and emerging doublet/triplet combinations that may limit ozekibart's incremental benefit.
Inhibrx's pipeline breadth remains narrow with only two clinical-stage candidates (ozekibart and INBRX-106), both dependent on multivalent sdAb platform success, and the absence of recent updates on preclinical programs or platform expansion efforts raises concerns about long-term sustainability beyond these two assets, especially given the company's history of divesting INBRX-101 to Sanofi and the potential for platform limitations to hinder next-generation candidate generation if the current candidates fail to deliver transformative results.

Customer Breakdown of Revenue (2025)

Peer Comparison

Companies in the Biotechnology

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	OCS	Oculis Holding AG	67,072.09 Bn	-31.30 Bn	-	-
2	NBTX	Nanobiotix S.A.	1,894.61 Bn	0.00 Bn	56,599.40	0.11 Bn
3	AKTX	Akari Therapeutics Plc	1,014.18 Bn	0.00 Bn	-	-
4	ONC	BeOne Medicines Ltd.	471.64 Bn	0.00 Bn	82.18	0.96 Bn
5	VRTX	Vertex Pharmaceuticals Inc / Ma	121.72 Bn	0.00 Bn	9.96	-
6	REGN	Regeneron Pharmaceuticals, Inc.	68.28 Bn	0.00 Bn	4.58	1.99 Bn
7	BLTE	Belite Bio, Inc	61.40 Bn	361.18 Bn	-	-
8	ARGX	Argenx Se	56.94 Bn	0.00 Bn	12.22	-

Research Tools

Developers

About

Investment Thesis

Customer Breakdown of Revenue (2025)

Customer Breakdown of Revenue (2025)

Peer Comparison

Research Tools

Developers

About

Investment Thesis

Customer Breakdown of Revenue (2025)

Customer Breakdown of Revenue (2025)

Peer Comparison

Create an account

Sign In

Reset Password